SEC Form 10-K filed by Summit Therapeutics Inc.
$SMMT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $12.00 | Underperform | Leerink Partners |
| 3/26/2025 | $23.00 → $35.00 | Neutral → Buy | Citigroup |
| 3/21/2025 | Overweight | Cantor Fitzgerald | |
| 3/12/2025 | $30.00 | Outperform | Evercore ISI |
| 2/28/2025 | $42.00 | Buy | Goldman |
| 1/8/2025 | $35.00 | Buy | Truist |
| 12/11/2024 | $30.00 | Overweight | Wells Fargo |
| 12/6/2024 | $31.00 | Buy | Jefferies |
Leerink Partners initiated coverage of Summit Therapeutics with a rating of Underperform and set a new price target of $12.00
Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously
Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight